市場調查報告書
商品編碼
1368663
糞便隱匿測試市場 - 按測試類型(癒創木脂 FOB 糞便測試、免疫 FOB 凝集測試、側流免疫 FOB 測試、免疫 FOB ELISA 測試)、最終用途(醫院、診斷中心) - 全球預測,20232- 2032Fecal Occult Testing Market - By Test Type (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test), By End-use (Hospitals, Diagnostic Centers) - Global Forecast, 20232-2032 |
由於越來越多的公眾意識活動和醫療保健舉措強調早期疾病檢測的重要性,糞便隱匿檢測市場規模預計從 2023 年到 2032 年將年複合成長率達到 7.3%。
糞便隱匿測試技術的不斷進步,例如開發更靈敏、更具體、更高準確性和可靠性的測試,正在促進市場的成長。此外,產業參與者正在實施策略性舉措,透過實施新型基因檢測方法來實現癌症篩檢現代化並改善醫療保健結果。舉個例子,2023 年 8 月,分子遺傳學診斷公司 Mainz Biomed NV 與 testDNA 合作,在波蘭商業推出 ColoAlert (R),旨在為被忽視的群體提供新的創新檢測替代方案。
糞便隱匿測試市場根據測試類型、最終用途和地區進行細分。
就測試類型而言,側流免疫FOB 領域的產業價值預計將在2023 年至2032 年期間獲得牽引力。這一成長可歸因於這種非侵入性測試在早期檢測糞便中隱藏血液中的採用率不斷上升樣本,作為胃腸道疾病(包括大腸癌)的重要篩檢工具。使用者友善性、高敏感性和預防性醫療措施的特異性等好處也將有助於該細分市場的成長。
由於改善病患照護和診斷以提供全面的醫療保健服務,到 2032 年,醫院最終用途領域的糞便隱匿檢測市場規模將大幅成長。隨著人們對預防保健和早期疾病檢測的日益重視,醫院正在採用糞便隱匿性檢測作為各種胃腸道疾病(包括大腸直腸癌和胃腸道出血)的常規篩檢工具。
亞太地區糞便隱匿檢測市場預計從2023 年到2032 年將以顯著的年複合成長率擴張。這歸因於人們對胃腸道健康意識的增強、結直腸癌發病率的上升以及基於人群的篩查計劃的實施。亞洲國家的幾個國家癌症中心之間為建立癌症預防教育和意識的長期框架而進行的多項合作努力將影響市場的成長。例如,亞洲國家癌症中心聯盟(ANCCA)擁有中國、印度、印尼、日本、韓國、蒙古、新加坡、泰國和越南等積極參與成員,規劃了 2020 年至 2031 年 ANCAA 的三個部分,包括協議亞洲特定癌症登記醫療標準。
Fecal Occult Testing Market size is estimated to record 7.3% CAGR from 2023-2032 attributed to the growing number of public awareness campaigns and healthcare initiatives emphasizing the importance of early disease detection.
The ongoing advancements in fecal occult testing technologies, such as the development of more sensitive and specific tests with improved accuracy and reliability are contributing to the market growth. Furthermore, industry participants are implementing strategic initiatives to modernize cancer screening and improve healthcare outcomes through the implementation of novel genetic testing methods. To cite an instance, in August 2023, Mainz Biomed NV, a molecular genetics diagnostic firm, partnered with testDNA for the commercial launch of ColoAlert® in Poland in a bid to advance new and innovative testing alternatives to neglected groups.
The fecal occult testing market is segmented in terms of test type, end-use, and region.
With respect to test type, the industry value from the lateral flow immuno FOB segment is expected to gain traction from 2023 to 2032. The growth can be attributed to the rising adoption of this non-invasive test in the early detection of hidden blood in stool samples, serving as vital screening tool for gastrointestinal conditions, including colorectal cancer. Benefits, such as user-friendly nature, high sensitivity, and specificity in preventive healthcare measures will also contribute to the segment growth.
Fecal occult testing market size from the hospitals end-use segment will grow at significant pace by 2032 due to the presence of improved patient care and diagnostics to offer comprehensive healthcare services. With the increasing focus on preventive healthcare and early disease detection, hospitals are adopting fecal occult testing as routine screening tool for various gastrointestinal disorders, including colorectal cancer and gastrointestinal bleeding.
Asia Pacific fecal occult testing market is set to expand at notable CAGR from 2023 to 2032. This is attributed to the increasing awareness about gastrointestinal health, rising incidences of colorectal cancer, and the implementation of population-based screening programs. Several collaboration efforts among several national cancer centers in Asian countries for creating long-term framework for education and awareness about cancer prevention will influence the market growth. For instance, the Asian National Cancer Centers Alliance (ANCCA) with active participating members, such as China, India, Indonesia, Japan, Korea, Mongolia, Singapore, Thailand, and Vietnam planned three segments of ANCAA from 2020 to 2031, including the protocol for Asian-specific medical standards for cancer registries.